SCHEMBL6800487

SCHEMBL6800487

CCOC(=O)CC(C)(C)Cc1ccc(O)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 2/20 0.38
POLB P06746 2/20 0.38
CYP3A4 P08684 2/20 0.38
MAPT P10636 2/20 0.38
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
ESR1 P03372 1/20 0.38
ESRRG P62508 1/20 0.38
USP2 O75604 1/20 0.38
EGFR P00533 1/20 0.38
FYN P06241 1/20 0.38
GAA P10253 1/20 0.38
APEX1 P27695 1/20 0.38
ADRA1A P35348 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6803905 0.88 SMN1; SMN2 (0.41) KDM4EALDH1A1PPIBPPIAPPID
SCHEMBL6803385 0.83 HSD17B2 (0.51) KDM4EALDH1A1CYP1A2POLBCYP3A4
SCHEMBL6809716 0.80 ESR1 (0.47) MEN1KMT2AESR1BLMCA12
SCHEMBL226654 0.80 YWHAG (0.50) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL6806028 0.79 MAPT (0.38) KDM4EALDH1A1MAPTALOX15HSD17B10
SCHEMBL2347025 0.77 CYP4F2 (0.58) CYP4F2CYP4A11APP
SCHEMBL15040339 0.76 MAPT (0.48) MEN1KMT2AALDH1A1CYP1A2CYP3A4
SCHEMBL12035708 0.75 CA12 (0.39) HPGDMEN1KMT2AALDH1A1CYP3A4
SCHEMBL6809494 0.74 KMT2A (0.48) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL12446623 0.72 ESR1 (0.52) HPGDMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043994-A1 Gem-substituted alpha v beta 3 antagonists PHARMACIA CORPORATION 2004-03-04 US disclosed
EP-1313705-A1 GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS Pharmacia Corporation (US) 2003-05-28 EP disclosed
US-6531494-B1 Gem-substituted αvβ3 antagonists PHARMACIA CORPORATION 2003-03-11 US disclosed
WO-2002018340-A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS PHARMACIA CORPORATION (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043994-A1 Gem-substituted alpha v beta 3 antagonists CACNG5, ITGAV, ITGA5 HPGD 3958/4885MEN1 1452/4885KMT2A 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.